1 / 11

HYSTORY: The Registry was established in 1996. AIM OF THE REGISTRY:

INTERNATIONAL REGISTRY of RECURRENT and FAMILIAL HEMOLYTIC UREMIC SYNDROME (HUS) and THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP). HYSTORY: The Registry was established in 1996. AIM OF THE REGISTRY: - understanding the pathogenesis of HUS/TTP

lapis
Download Presentation

HYSTORY: The Registry was established in 1996. AIM OF THE REGISTRY:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. INTERNATIONAL REGISTRY of RECURRENT and FAMILIAL HEMOLYTIC UREMIC SYNDROME (HUS) and THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) HYSTORY: The Registry was established in 1996. AIM OF THE REGISTRY: - understanding the pathogenesis of HUS/TTP - studying the genetic and biochemical abnormalities of HUS/TTP - finding the best therapeutic approach for patients - collecting clinical and genetic data of patients and their families - giving up-to-date information to physicians and families

  2. THE THROMBOTIC MICROANGIOPATHY (TMA) The term “thrombotic microangiopathy” (TMA) defines a lesion of vessel wall thickening (mainly arterioles and capillaries), intraluminal platelet thrombosis and partial or complete obstruction of the vessel lumina1. HUSmicroangiopathic haemolysis, thrombocytopenia and renal failure TTP microangiopathic haemolysis, thrombocytopenia and cerebral lesions HUS and TTP are entities pathologically indistinguishable 1 Caprioli J. et al. Human Molecular Genetics, 2003, Vol. 12, No. 24: 3385-3395

  3. FORMS OF HUS/TTP: The most common form of HUS in children, with predominant renal failure, is associated with a particular gastro-intestinal infection. This form usually has an excellent prognosis. There are also rare forms of HUS/TTP without gastro-intestinal infection, that have a much poorer prognosis: - relapsing form (when the patient has severaò relapses of the disease) - familial form (when there are at least 2 subjects with HUS/TTP in the same family) TTP is the most common form of TMA in adults and manifests with prevailing neurological symptoms.

  4. THERAPY OF HUS/TTP: Early plasma-exchange or plasma infusion of an health donor are the current therapies for acute phases of the disease. Dialysis is necessary if there is an acute renal failure

  5. HOW FAR IS RESEARCH? There are a lot of research studies ongoing about HUS/TTP to understand the pathogenesis and to find the specific therapies of the disease. Researchers involving are studying the role of substances of the blood coagulation and particularly some proteins of the complement system, and are studying the genetic aspects of HUS/TTP. As for therapy: research is working on the optimisation of plasma treatment for patients.

  6. WHAT OUR RESEARCH LABORATORY OF THE REGISTRY IS DOING TO BETTER UNDERSTAND HUS/TTP? GENETIC AND BIOCHEMICAL STUDIES ON: Factor H– CFH - a plasmatic circulating protein produced by the liver and involved in the regulation of the complement system, that is often spoiled in patients with HUS. Membrane Cofactor Protein – MCP - a complement regulatory protein. Recently our researchers have found a mutation of MCP gene in a family with HUS. ADAMTS13 – the Von Willebrand Factor cleaving protease – an enzyme which degrades the VWF multimers, preventing platelet adhesion and aggregation in the microcirculation. The plasma levels of ADAMTS13 protease in some patients (particularly with TTP) are absent or very low, due to a constitutive or acquired defective activity. 2 Noris M. et al. Lancet, 2003, Vol. 362: 1542-1547

  7. WHAT THE REGISTRY RESEARCHERS ARE DOING? Recently* our researchers found 17 different mutations in the factor H gene of 33 patients with HUS referred to the Registry. 3 Caprioli et al. Human Molecular Genetics, 2003, Vol. 12, No. 24: 3385-3395

  8. L R Trp1183Arg Trp1183Arg 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 T T A A W W K K R R Q Q L L K K H A A W H L L I I Cys1163Trp G Tyr951His Y Y N N STOP Gln950His S S Arg60Gly Y Y STOP STOP R R del A1494-1496 D D N N Gly1194Asp Gly1194Asp T T E E Glu1172Stop Glu1172Stop G G M M STOP STOP E E I I A A S S E E Val1197Ala Val1197Ala A A V V R R COOH NH2 E E L L K K E E S S Y Y G G I I F F P P D D Glu1198Ala A A V V T T V V W W C C C C C C C C NH2 NH2 P P H H T T A A K K K K T T R COOH R R R R G G L L Y Y Q Q T T R R STOP H H STOP Arg1215Gln Arg1215Gln L L S S S S S S R R 24 bp deletion 24 bp deletion C C C C C C Arg1210Cys Arg1210Cys MUTATIONS FOUND IN FACTOR H GENE FROM PATIENTS REFERRED TO THE REGISTRY

  9. PARTICIPATING CENTERS OF THE INTERNATIONAL REGISTRY OF HEMOLYTIC UREMIC SYNDROME AND THROMBOTIC THROMBOCYTOPENIC PURPURA: Italian Centers: 72 Abroad Centers: 39 Bergamo DENMARK U.S.A UK CANADA BELGIUM GERMANY ARGENTINA SWITZERLAND RSA PORTUGAL SAUDI ARABIA SPAIN ISRAEL

  10. THE INTERNATIONAL REGISTRY OF HUS/TTP: PATIENTS DATA

  11. CONTACTS We perform biochemical and genetic analyses for patients with atypical form of HUS/TTP. For information and for other questions and for any other questions, please contact: Clinical Research Center for Rare Diseases Aldo e Cele Daccò Mario Negri Institute for Pharmacological Research Via G.B. Camozzi, 3 -24020- Ranica (BG) Italy Phone: +39-035-4535304 Fax: +39-035-4535373 E-mail: raredis@marionegri.it Contact persons: Elena Bresin, MD Erica Daina, MD Sara Gamba, RN INTERNATIONAL REGISTRY FOR HAEMOLYTICAL URAEMIC SYDROME (HUS) AND THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)

More Related